参考文献/References:
[1] Tamis-Holland JE,Jneid H,Reynolds HR,et al. Contemporary diagnosis and management of patients with myocardial infarction in the absence of obstructive coronary artery disease: a scientific statement from the American Heart Association[J]. Circulation,2019,139(18):e891-e908.
[2] Agewall S,Beltrame JF,Reynolds HR,et al. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries[J]. Eur Heart J,2017,38(3):143-153.
[3] Pustjens T,Appelman Y,Damman P,et al. Guidelines for the management of myocardial infarction/injury with non-obstructive coronary arteries (MINOCA): a position paper from the Dutch ACS working group[J]. Neth Heart J,2020,28(3):116-130.
[4] Ibanez B,James S,Agewall S,et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)[J]. Eur Heart J,2018,39(2):119-177.
[5] Thygesen K,Alpert JS,Jaffe AS,et al. Fourth universal definition of myocardial infarction (2018)[J]. Circulation,2018,138(20):e618-e651.
[6] Fahed AC,Jang IK. Plaque erosion and acute coronary syndromes: phenotype,molecular characteristics and future directions[J]. Nat Rev Cardiol,2021,18(10):724-734.
[7] 胥日,羊镇宇. 冠状动脉非阻塞性心肌梗死的发病机制及影像学表现[J]. 心血管病学进展,2021,42(2):148-152.
[8] Vranken NPA,Pustjens TFS,Kolkman E,et al. MINOCA:the caveat of absence of coronary obstruction in myocardial infarction[J]. Int J Cardiol Heart Vasc,2020,29:100572.
[9] Nordenskj?ld AM,Eggers KM,Jernberg T,et al. Circadian onset and prognosis of myocardial infarction with non-obstructive coronary arteries (MINOCA)[J]. PLoS One,2019,14(4):e216073.
[10] Kunadian V,Chieffo A,Camici PG,et al. An EAPCI expert consensus document on ischaemia with non-obstructive coronary arteries in collaboration with european society of cardiology working group on coronary pathophysiology & microcirculation endorsed by coronary vasomotor disorders international study group[J].Eur Heart J,2020,41(37):3504-3520.
[11] Beltrame JF,Psaltis PJ. The forgotten vascular layer in the forgotten coronary disorder[J]. J Am Coll Cardiol,2018,71(4):426-428.
[12] Tanaka A,Taruya A,Shibata K,et al. Coronary artery lumen complexity as a new marker for refractory symptoms in patients with vasospastic angina[J]. Sci Rep,2021,11(1):13.
[13] Opolski MP. Mechanisms of myocardial infarction with nonobstructive coronary atherosclerosis: a multifaceted play of different actors with guarded prognosis[J]. Curr Opin Cardiol,2020,35(6):697-704.
[14] Kim E. Spontaneous coronary-artery dissection[J]. N Engl J Med,2020,383(24):2358-2370.
[15] Saw J,Humphries K,Aymong E,et al. Spontaneous coronary artery dissection: clinical outcomes and risk of recurrence[J]. J Am Coll Cardiol,2017,70(9):1148-1158.
[16] Taqueti VR,di Carli MF. Coronary microvascular disease pathogenic mechanisms and therapeutic options:JACC state-of-the-art review[J]. J Am Coll Cardiol,2018,72(21):2625-2641.
[17] Sanchis J,Garcia-Blas S,Ortega-Paz L,et al. Cell-free DNA and microvascular damage in st-segment elevation myocardial infarction treated with primary percutaneous coronary intervention[J]. Rev Esp Cardiol(Engl Ed),2019,72(4):317-323.
[18] Montenegro SF,Carvalho R,Santos L,et al. Dual antiplatelet therapy in myocardial infarction with non-obstructive coronary artery disease - insights from a nationwide registry[J]. Rev Port Cardiol (Engl Ed),2020,39(12):679-684.
[19] Lindahl B,Baron T,Erlinge D,et al. Medical therapy for secondary prevention and long-term outcome in patients with myocardial infarction with nonobstructive coronary artery disease[J]. Circulation,2017,135(16):1481-1489.
[20] Volpato G,Falanga U,Cipolletta L,et al. Sports activity and arrhythmic risk in cardiomyopathies and channelopathies: a critical review of European Guidelines on sports cardiology in patients with cardiovascular diseases[J]. Medicina (Kaunas,Lithuania),2021,57(4):308.
[21] Ciliberti G,Verdoia M,Merlo M,et al. Pharmacological therapy for the prevention of cardiovascular events in patients with myocardial infarction with non-obstructed coronary arteries (MINOCA): Insights from a multicentre national registry[J]. Int J Cardiol,2021,327:9-14.
[22] Ortega-Paz L,Galli M,Capodanno D,et al. The role of antiplatelet therapy in patients with MINOCA[J]. Front Cardiovasc Med,2021,8:821297.
[23] Abdu FA,Liu L,Mohammed A,et al. Myocardial infarction with non-obstructive coronary arteries (MINOCA) in Chinese patients:clinical features,treatment and 1?year follow-up[J]. Int J Cardiol,2019,287:27-31.
[24] Kowara M,Cudnoch-Jedrzejewska A. Different approaches in therapy aiming to stabilize an unstable atherosclerotic plaque[J]. Int J Mol Sci,2021,22(9):4354.
[25] Kurihara O,Takano M,Kakuta T,et al. Determinants of ST-segment elevation myocardial infarction as clinical presentation of acute coronary syndrome[J]. J Thromb Thrombolysis,2020,51(4):1026-1035.
[26] Xing L,Yamamoto E,Sugiyama T,et al. EROSION study (effective anti-thrombotic therapy without stenting: intravascular optical coherence tomography-based management in plaque erosion): a 1-year follow-up report[J]. Circ Cardiovasc Interv,2017,10(12):e005860.
[27] Almendro-Delia M,Blanco-Ponce E,Carmona-Carmona J,et al. Comparative safety and effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndrome: an on-treatment analysis from a multicenter registry[J]. Front Cardiovasc Med,2022,9:887748.
[28] Yokoi H,Oda E,Kaneko K,et al. Duration and clinical outcome of dual antiplatelet therapy after percutaneous coronary intervention:a retrospective cohort study using a medical information database from Japanese hospitals[J]. Cardiovasc Interv Ther,2022,37(3):465-474.
[29] Cho SS,Jo SH,Han SH,et al. Clopidogrel plus aspirin use is associated with worse long-term outcomes,but aspirin use alone is safe in patients with vasospastic angina: results from the VA-Korea registry,a prospective multi-center cohort[J]. Sci Rep,2019,9(1):17783.
[30] Lin Y,Chen Y,Yuan J,et al. Impact of aspirin use on clinical outcomes in patients with vasospastic angina: a systematic review and meta-analysis[J]. BMJ Open,2021,11(7):e48719.
[31] García-Guimaraes M,Bastante T,Macaya F,et al. Spontaneous coronary artery dissection in Spain: clinical and angiographic characteristics,management,and in-hospital events[J]. Rev Esp Cardiol(Engl Ed),2021,74(1):15-23.
[32] Bairey MC,Pepine CJ,Shimokawa H,et al. Treatment of coronary microvascular dysfunction[J]. Cardiovasc Res,2020,116(4):856-870.
[33] Bechsgaard DF,Prescott E. Coronary microvascular dysfunction: a practical approach to diagnosis and management[J]. Curr Atheroscler Rep,2021,23(9):54.
[34] Vancheri F,Longo G,Vancheri S,et al. Coronary microvascular dysfunction[J]. J Clin Med,2020,9(9):2880.
相似文献/References:
[1]周召锋,吴春阳.急性冠状动脉综合征的抗血小板治疗进展[J].心血管病学进展,2015,(5):646.[doi:10.3969/j.issn.1004-3934.2015.05.032]
ZHOU Zhaofeng,WU Chunyang.Development of Antiplatelet Therapy for Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2015,(10):646.[doi:10.3969/j.issn.1004-3934.2015.05.032]
[2]徐俊波 黄刚 蔡琳 刘汉雄 张廷杰.老老年患者抗血小板治疗的循证临床实践[J].心血管病学进展,2019,(8):1123.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.013]
XU Junbo,HUANG Gang,CAI Lin,et al.Evidence-based Antiplatelet Treatment in Very Elderly Patients in Clinical Practice[J].Advances in Cardiovascular Diseases,2019,(10):1123.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.013]
[3]朱志伦 田乃亮.急性冠脉综合征患者抗血小板降阶治疗方案研究进展[J].心血管病学进展,2021,(6):534.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.014]
ZHU Zhilun,TIAN Nailiang.Advances in De-Escalation of Anti-Platelet Therapy in Patients with Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2021,(10):534.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.014]
[4]王亚辉 杨滨.血液透析对行经皮冠状动脉介入治疗的患者合用阿司匹林及氯吡格雷抗血小板聚集的影响[J].心血管病学进展,2021,(10):946.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.020]
WANG YahuiYANG Bin.Effect of Hemodialysis on the Antiplatelet Aggregation of Patients Undergoing Percutaneous Coronary Intervention Combined with Aspirin and Clopidogrel[J].Advances in Cardiovascular Diseases,2021,(10):946.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.020]
[5]陈纪元 陆泓雨 贺子熠 韩江莉.冠心病合并慢性肾脏病患者P2Y12受体拮抗剂治疗进展[J].心血管病学进展,2022,(7):582.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
CHEN Jiyuan,LU Hongyu,HE Ziyi,et al.P2Y12 Antagonists for Patients with Chronic Kidney Diseases and Coronary Heart Diseases[J].Advances in Cardiovascular Diseases,2022,(10):582.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[6]闫海浩 张飞飞 党懿.光学相干断层成像在冠状动脉非阻塞性心肌梗死中的应用[J].心血管病学进展,2022,(10):883.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.005]
YAN Haihao,ZHANG Feifei,DANG Yi.Application of Optical Coherence Tomography in Myocardial Infarction with Non-Obstructive Coronary Arteries[J].Advances in Cardiovascular Diseases,2022,(10):883.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.005]
[7]刘娟 熊诗强 蔡琳.经皮冠状动脉介入治疗术后出血风险评估研究进展[J].心血管病学进展,2023,(4):303.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.004]
LIU Juan,XIONG Shiqiang,CAI Lin.Bleeding Risk Assessment After Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2023,(10):303.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.004]
[8]吕易非 李紫凡 邵褀睿 韩江莉.急性冠脉综合征合并高出血风险患者双联抗血小板治疗研究进展[J].心血管病学进展,2023,(7):577.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.001]
LV Yifei,LI Zifan,SHAO Qirui,et al.Dual Antiplatelet Therapy for Patients with Acute Coronary Syndrome and High Bleeding Risk[J].Advances in Cardiovascular Diseases,2023,(10):577.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.001]
[9]努尔古丽·玉苏普 古力尼尕尔·麦麦提吐尔孙 陈清杰 艾尔肯·阿吉.急性冠脉综合征合并糖尿病患者P2Y12受体拮抗剂治疗进展[J].心血管病学进展,2023,(7):593.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.005]
Nurgul·Yusup,Gulinigar·Mamattursun,CHEN Qingjie,et al.P2Y12 Receptor Antagonist Therapy in A cute Coronary Syndrome with Diabetes[J].Advances in Cardiovascular Diseases,2023,(10):593.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.005]
[10]崔鸿杰 吴英锋.CYP2C19基因多态性指导抗血小板治疗的研究现状[J].心血管病学进展,2023,(11):1019.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.014]
Cui Hongjie,Wu Yingfeng.CYP2C19 gene polymorphism for antiplatelet therapy[J].Advances in Cardiovascular Diseases,2023,(10):1019.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.014]